Drugs / FHND1002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06782958 | Jul 2024 → Mar 2025 overdue | amyotrophic lateral sclerosis | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07138014 | Oct 2025 → Dec 2027 expected | amyotrophic lateral sclerosis | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-28 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Regulatory 公司1.1类新药神经保护剂FHND1002获批临床 ctfh.com.cn ↗
12 月27日，江苏正大丰海制药有限公司自主研发的First-in-Class新药—FHND1002，获中国国家药品监督管理局（NMPA）批准开展药物临床试验，本次获批适应症为肌萎缩性侧索硬化（ALS，俗称渐冻人症）和缺血性脑卒中。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-28 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 公司1.1类新药神经保护剂FHND1002获批临床 ctfh.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FHND1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07138014 ↗ |
| Route | Oral | “daily oral dose of FHND1002 granules” NCT06782958 ↗ |